Clinical Trials Logo

Clinical Trial Summary

Carotid baroreflex activation therapy (BAT) by the Rheos® system produces a sustained fall in blood pressure in patients with resistant hypertension. Since the activation electrodes are implanted at the level of the carotid sinus, it is conceivable that the nearby located carotid body chemoreceptors are stimulated as well. Physiological stimulation of carotid chemoreceptors not only raises respiration, but it also increases sympathetic activity which may in part counteract the effects of BAT. The aim of the present study is to investigate whether there is evidence for concomitant carotid chemoreflex activation during BAT. We hypothesized that there is no clinically relevant co-activation of the carotid body chemoreceptors during BAT in patients with resistant hypertension.


Clinical Trial Description

n/a


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT02210923
Study type Observational
Source Maastricht University Medical Center
Contact Teba Alnima, MD
Phone 003143 3875367
Email teba.alnima@mumc.nl
Status Recruiting
Phase N/A
Start date October 2013

See also
  Status Clinical Trial Phase
Terminated NCT02539810 - Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA) Phase 4
Completed NCT02832973 - Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension Phase 4
Completed NCT02282033 - Safety and Performance Study of the Moderato System N/A
Completed NCT01173029 - Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events N/A
Active, not recruiting NCT02837445 - Moderato System: A Double-Blind Randomized Trial Ver 1.1 N/A
Terminated NCT02653222 - Chemical Renal Ethanol Sympatholysis Under CT Guidance Use for the Control of Therapy-Resistant Hypertension Phase 2
Recruiting NCT02690909 - A Study to Evaluate Safety and Efficacy of the Redy™ Renal Denervation System in the Treatment of Patients With Uncontrolled Hypertension N/A